Showing 1 - 10 of 383
We study the effect of price caps on the provision of costly effort by pharmaceutical firms using variation in drug discounts generated by a price regulation program that allows eligible hospitals to purchase outpatient drugs at steep discounts. These discounts directly affect drug...
Persistent link: https://www.econbiz.de/10014512103
We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a …
Persistent link: https://www.econbiz.de/10012470978
We examine the role of network effects in the demand for pharmaceuticals at both the brand level and for a therapeutic …
Persistent link: https://www.econbiz.de/10012471776
I use variation in approval time for generic drugs to shed light on the objectives of the federal agency in charge of granting entry permission for these drugs (FDA). Applications belonging to firms later found to have engaged in fraud or corruption were approved nine months faster on average,...
Persistent link: https://www.econbiz.de/10012472670
We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to...
Persistent link: https://www.econbiz.de/10012474690
Economic literature has extensively studied how prices for incumbent pharmaceutical drugs respond to generic competition after entry. However, less attention has been paid to pricing behavior in anticipation of brand-to-brand competition. We contribute to this gap in the literature by both...
Persistent link: https://www.econbiz.de/10012453327
branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …
Persistent link: https://www.econbiz.de/10012462361
EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on...
Persistent link: https://www.econbiz.de/10012465985
There is a long-standing literature that recognizes that an efficient solution in correcting a consumption externality is through applying subsidies and taxes that line up private incentives with social ones. An equally long-standing literature tackles the appropriate methods of generating the...
Persistent link: https://www.econbiz.de/10012469100
This paper analyzes determinants of ex-manufacturer prices for originator and generic drugs across a large sample of countries. We focus on drugs to treat HIV/AIDS, TB and malaria in middle and low income countries (MLICs), with robustness checks to other therapeutic categories and other...
Persistent link: https://www.econbiz.de/10012461483